SLIDE 1
Workshop Objective and Agenda
2
Realizing the Benefits of Connected Health in Respiratory Drug - - PowerPoint PPT Presentation
Realizing the Benefits of Connected Health in Respiratory Drug - - PowerPoint PPT Presentation
Realizing the Benefits of Connected Health in Respiratory Drug Delivery RDD Europe 26.04.2017 Bill Welch, CTO Phillips-Medisize Kevin Deane, EVP Medicom Innovation Partner Workshop Objective and Agenda Opportunities and Challenges in
SLIDE 2
SLIDE 3
Workshop Presentation „Realizing the Benefits of Connected Health in Respiratory Drug Delivery”
3
- Developing a value proposition and connected device strategy
- Treating & Monitoring Chronic Respiratory Diseases
- Making the transition from clinicals to real-world scale-up
- Brainstorming session on Opportunities and challenges with Connected Health in
Respiratory therapies
SLIDE 4
The healthcare industry faces significant challenges
4
- Healthcare costs are rising globally at an unsustainable level, placing greater scrutiny on prescription
medicine prices, even though these account for only about 10% of overall spend
- This places an ever increasing pressure on drug costs, with payers exerting greater buying pressure to
reduce prescription medicine spend and achieve greater affordability for patients and providers
- For many years the discussion has been moving towards ‘payment by result’, reimbursement based on
- utcome models
- This is changing the way that pharma approaches drug development, pricing and launch
SLIDE 5
At the same time dosage forms are evolving and connected devices proliferate
5
- Devices are the norm for new medicinal treatments for
chronic diseases
- Increasingly complex, targeted and personalized drugs
mean devices will be ever more critical to patient acceptance and drug performance
…while connectivity is becoming ubiquitous
- More connected devices than people
- By 2020 the average person will have as many 6 ‘things’ on-line
- The uptake rate of digital infrastructure is occurring at a rate 5
times faster than the adoption rate of electricity and telephones
The value of drugs delivered through devices has increased 10-fold in 10 years
SLIDE 6
With all of these challenges, how do Pharmaceutical R&D groups respond?
6
Inputs Outputs Outcomes Cost per launch Value per launch R&D efficiency More affordable drugs via less costly R&D R&D effectiveness More value for the patient and the system via innovative drugs with high-quality information
- Much of the R&D productivity effort is focused on
efficiency: > Streamlining internal development costs > Outsourcing non-core activities > Licensing in higher risk candidate drugs > Adopting a ‘fast to fail’ approach
- Whereas R&D effectiveness focuses on patients, with
drug delivery integral to the strategy: > It defines the therapy specific value that can be delivered to the patient and to other stakeholders > It defines opportunities of how this value can be delivered > And, it defines how therapy information should flow securely transfer data to healthcare providers and stakeholders
Broadly, R&D productivity is the combination of efficiency and effectiveness
Adopt a Patient-centric approach: For many drugs entering the market, the method of drug delivery becomes the key connection point between the drug (and by extension, the pharma company) and the patient. Therefore, devices and associated technologies are central to patient value and the determination of outcome benefit.
Source: Nature Reviews Drug Discovery 9, 203-214 (March 2010)
SLIDE 7
Workshop Presentation „Realizing the Benefits of Connected Health in Respiratory Drug Delivery”
7
- Developing a value proposition and connected device strategy
- Treating & Monitoring Chronic Respiratory Diseases
- Making the transition from clinicals to real-world scale-up
- Brainstorming session on Opportunities and challenges with Connected Health in
Respiratory therapies
SLIDE 8
Connected health for improved Patient-centered treatment setup and outcome
8
SLIDE 9
A Connected Health approach should cover the entire Patient Care Journey
9
Patient Care Journey
Pre-prescription Retention Prescription Improve
Selling the DRUG Pre-prescription/Sales HCP training Disease awareness Sales rep. engagement Information sharing Delivering OUTCOME Operational Adherence/motivation Direct treatment impact Patient, Caregiver and HCP interaction
SLIDE 10
General structure of a fully Connected Respiratory Health Service Setup
10
SLIDE 11
Comparing to the well-known Fitbit approach…
11
Medication adherence tracking Social engagement and motivation Auxiliary data and patient information Supporting (seemless) patient monitoring
SLIDE 12
Workshop Presentation „Realizing the Benefits of Connected Health in Respiratory Drug Delivery”
12
- Developing a value proposition and connected device strategy
- Treating & Monitoring Chronic Respiratory Diseases
- Making the transition from clinicals to real-world scale-up
- Brainstorming session on Opportunities and challenges with Connected Health in
Respiratory therapies
SLIDE 13
Our approach starts with needs and opportunities, identifying ‘best fit’ technologies at the end
13
Research on market opportunities and unmet needs in relation to the therapy, the competitive situation Identify technological platforms that support the identified therapy specific device drivers. Split up in short and long term (LCM)
- ptions
Take into account constraints and uncertainties that exist around the specific case – both internally and externally Identify drivers for execution in respect to segmentation, launch and development
Working areas of a drug delivery strategy:
SLIDE 14
Integrated Device Development – a logical outcome of Device Strategy
14
The Phillips-Medisize Value Proposition: Integrated Product and Manufacturing Development leads to reduced time-to-market and lower launch risk
SLIDE 15
Summary
15
- Leverage partners with proven connected health experience in both
drug delivery devices and software
§ Choose a partner & platform technology that can support your
longer-term vision and advancing market expectations
- Require platform approach that can be tailored to your needs, yet is
extensible across your business as your connected health strategy and areas of disease focus evolve
- Address your drug delivery device needs and primary packaging
components early – to get a competitive advantage in your therapies
- Use both Device Strategy to address an outcome-based solution,
and a Manufacturing Strategy to get to market at target quality, cost, time, and risk
SLIDE 16